Saturday 17 October 2026
Export INSM’s income statement to Excel — free account
Insmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024. In the quarter to June 2026, revenue grew 296.1%, EPS grew 96.5%, free cash flow grew 54.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
96.27
2.94
−2.96%
Follow INSM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
68.22 | 57.12 | 42.99 | 20.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(138.77) | (139.89) | (158.18) | (260.89) | |
P/B ratio |
32.25 | 46.87 | 49.99 | 30.59 | |
Price to Tangible BV |
42.07 | 68.56 | 74.46 | 43.90 | |
EV/Sales |
66.22 | 56.05 | 42.46 | 20.04 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(33.51) | (36.35) | (38.85) | (29.27) | |
EV/FCF |
(32.67) | (35.13) | (37.75) | (28.23) | |
Quick Ratio |
4.18 | 3.35 | 3.88 | 3.14 | |
Current Ratio |
4.63 | 3.83 | 4.47 | 3.72 | |
Net Debt/EBITDA |
3.11 | 2.78 | 4.52 | (102.75) | |
Debt/Assets |
23.78% | 24.80% | 27.07% | 26.75% | |
Debt/Equity |
0.59 | 0.76 | 0.80 | 0.74 | |
Asset Turnover |
0.20 | 0.28 | 0.42 | 0.50 | |
Operating CF/Net income |
0.59 | 0.75 | 1.36 | 6.71 | |
Capex/Depreciation |
(0.40) | (2.18) | (0.49) | (0.85) | |
Interest Coverage |
(17.96) | (15.52) | (7.63) | (0.08) | |
Research and Development Expense of Revenue |
130.96% | 96.61% | 68.47% | 49.36% | |
Selling, General and Administrative Expense of Revenue |
130.94% | 80.53% | 80.81% | 58.16% | |
Intangible Assets out of Total Assets |
0.09 | 0.10 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
22.08% | 14.80% | 14.95% | 9.70% | |
Graham Net Nets |
0.02 | 0.01 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.30%) | (3.68%) | (3.52%) | (3.85%) | |
Free Cash Flow Yield |
(2.97%) | (2.79%) | (2.62%) | (3.49%) | |
Revenue per Share |
0.67 | 1.33 | 1.42 | 1.96 | |
Operating CF per Share |
(1.04) | (1.24) | (1.03) | (0.41) | |
Capex per Share |
(0.01) | (0.08) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(1.05) | (1.33) | (1.05) | (0.44) | |
Cash per Share |
7.93 | 7.19 | 5.68 | 5.34 | |
Shareholders Equity per Share |
4.47 | 3.71 | 3.27 | 3.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.47 | 3.71 | 3.27 | 3.49 | |
Free Cash Flow |
(222.18) | (264.18) | (226.22) | (95.09) | |
Working Capital |
1,514.59 | 1,325.33 | 1,252.17 | 1,195.18 | |
Capital Expenditures |
(2.42) | (16.59) | (3.48) | (6.26) | |
Net Current Asset Value |
516.64 | 268.63 | 242.16 | 288.85 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.06 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
53.79 | 96.43 | 113.15 | 135.18 | |
Average Payables |
329.26 | 370.63 | 292.61 | 366.97 | |
Average Inventory |
109.72 | 115.32 | 116.81 | 124.99 | |
Average Assets |
2,206.85 | 2,144.89 | 1,939.30 | 2,291.21 | |
Average Common Equity |
714.49 | 512.18 | 402.01 | 1,003.61 |
Columns are period end dates